angel oak mortgage reit inc - LYEL
LYEL
Close Chg Chg %
38.60 -3.51 -9.09%
Closed Market
35.09
-3.51 (9.09%)
Volume: 127.52K
Last Updated:
Dec 26, 2025, 4:00 PM EDT
Company Overview: angel oak mortgage reit inc - LYEL
LYEL Key Data
| Open $38.63 | Day Range 34.52 - 38.63 |
| 52 Week Range 7.65 - 45.00 | Market Cap $820.02M |
| Shares Outstanding 21.24M | Public Float 6.94M |
| Beta -0.11 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$22.95 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 103.06K |
LYEL Performance
| 1 Week | 5.28% | ||
| 1 Month | 46.21% | ||
| 3 Months | 173.50% | ||
| 1 Year | 169.92% | ||
| 5 Years | N/A |
LYEL Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
3
Full Ratings ➔
About angel oak mortgage reit inc - LYEL
Lyell Immunopharma, Inc. operates as a holding company, which engages in the development of cell-based immunotherapies for human diseases. The company was founded by Richard D. Klausner, Stan Riddell, and Crystal Mackall in June 2018 and is headquartered in South San Francisco, CA.
LYEL At a Glance
Lyell Immunopharma, Inc.
201 Haskins Way
South San Francisco, California 94080
| Phone | 1-650-695-0677 | Revenue | 61.00K | |
| Industry | Biotechnology | Net Income | -342,994,000.00 | |
| Sector | Health Technology | Employees | 300 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
LYEL Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 2,743.397 |
| Price to Book Ratio | 0.493 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.706 |
| Enterprise Value to Sales | -2,364.128 |
| Total Debt to Enterprise Value | -0.409 |
LYEL Efficiency
| Revenue/Employee | 203.333 |
| Income Per Employee | -1,143,313.333 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.00 |
LYEL Liquidity
| Current Ratio | 7.057 |
| Quick Ratio | 7.057 |
| Cash Ratio | 6.889 |
LYEL Profitability
| Gross Margin | -32,081.967 |
| Operating Margin | -367,034.426 |
| Pretax Margin | -562,285.246 |
| Net Margin | -562,285.246 |
| Return on Assets | -55.282 |
| Return on Equity | -66.102 |
| Return on Total Capital | -77.637 |
| Return on Invested Capital | -59.877 |
LYEL Capital Structure
| Total Debt to Total Equity | 15.403 |
| Total Debt to Total Capital | 13.347 |
| Total Debt to Total Assets | 12.013 |
| Long-Term Debt to Equity | 13.32 |
| Long-Term Debt to Total Capital | 11.543 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Angel Oak Mortgage Reit Inc - LYEL
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 10.65M | 84.68M | 130.00K | 61.00K | |
Sales Growth
| +37.31% | +695.15% | -99.85% | -53.08% | |
Cost of Goods Sold (COGS) incl D&A
| 14.54M | 16.47M | 20.25M | 19.63M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 14.54M | 16.47M | 20.25M | 19.63M | |
Depreciation
| 14.54M | 16.47M | 20.25M | 19.63M | |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| +94.45% | +13.29% | +22.97% | -3.06% | |
Gross Income
| (3.88M) | 68.22M | (20.12M) | (19.57M) | |
Gross Income Growth
| -1,482.56% | +1,855.88% | -129.49% | +2.73% | |
Gross Profit Margin
| -36.48% | +80.55% | -15,476.92% | -32,081.97% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 213.22M | 260.03M | 230.61M | 204.32M | |
Research & Development
| 124.16M | 142.72M | 163.63M | 152.28M | |
Other SG&A
| 89.06M | 117.31M | 66.98M | 52.04M | |
SGA Growth
| -3.81% | +21.96% | -11.31% | -11.40% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 32.99M | 11.20M | 14.77M | 156.14M | |
EBIT after Unusual Expense
| (250.09M) | (203.01M) | (265.50M) | (380.03M) | |
Non Operating Income/Expense
| (129.00K) | 19.89M | 30.87M | 37.04M | |
Non-Operating Interest Income
| 1.17M | 7.05M | 23.45M | 24.07M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | - | - |
Interest Expense Growth
| - | - | - | - | - |
Gross Interest Expense
| - | - | - | - | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (250.22M) | (183.12M) | (234.63M) | (342.99M) | |
Pretax Income Growth
| -22.37% | +26.82% | -28.13% | -46.18% | |
Pretax Margin
| -2,349.47% | -216.24% | -180,486.15% | -562,285.25% | |
Income Tax
| - | - | - | - | - |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (250.22M) | (183.12M) | (234.63M) | (342.99M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (250.22M) | (183.12M) | (234.63M) | (342.99M) | |
Net Income Growth
| -22.37% | +26.82% | -28.13% | -46.18% | |
Net Margin Growth
| -2,349.47% | -216.24% | -180,486.15% | -562,285.25% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (250.22M) | (183.12M) | (234.63M) | (342.99M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (250.22M) | (183.12M) | (234.63M) | (342.99M) | |
EPS (Basic)
| -20.6164 | -14.8226 | -18.697 | -26.2348 | |
EPS (Basic) Growth
| -22.17% | +28.10% | -26.14% | -40.32% | |
Basic Shares Outstanding
| 12.14M | 12.35M | 12.55M | 13.07M | |
EPS (Diluted)
| -20.6164 | -14.8226 | -18.697 | -26.2348 | |
EPS (Diluted) Growth
| -22.17% | +28.10% | -26.14% | -40.32% | |
Diluted Shares Outstanding
| 12.14M | 12.35M | 12.55M | 13.07M | |
EBITDA
| (202.56M) | (175.34M) | (230.48M) | (204.26M) | |
EBITDA Growth
| +5.30% | +13.44% | -31.44% | +11.38% | |
EBITDA Margin
| -1,902.02% | -207.06% | -177,290.77% | -334,852.46% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 21.333 | |
| Number of Ratings | 3 | Current Quarters Estimate | -2.37 | |
| FY Report Date | 12 / 2025 | Current Year's Estimate | -10.608 | |
| Last Quarter’s Earnings | -2.13 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -26.249 | Next Fiscal Year Estimate | -9.053 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 4 | 2 | 4 | 4 |
| Mean Estimate | -2.37 | -2.14 | -10.61 | -9.05 |
| High Estimates | -1.83 | -2.12 | -10.04 | -7.35 |
| Low Estimate | -3.36 | -2.16 | -11.92 | -9.78 |
| Coefficient of Variance | -29.40 | -1.32 | -8.30 | -12.62 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 2 | 1 | 1 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 0 | 1 | 1 |
| UNDERWEIGHT | 1 | 1 | 1 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Hold | Hold |
SEC Filings for Angel Oak Mortgage Reit Inc - LYEL
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Angel Oak Mortgage Reit Inc - LYEL
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Feb 27, 2025 | Lynn Seely President and CEO; Director | 537,500 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2025 | Lynn Seely President and CEO; Director | 1,350,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2025 | Lynn Seely President and CEO; Director | 168,750 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2025 | Matthew Lang Chief Business Officer | 162,500 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2025 | Matthew Lang Chief Business Officer | 450,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2025 | Matthew Lang Chief Business Officer | 56,250 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2025 | Gary Lee Chief Scientific Officer | 176,696 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2025 | Gary Lee Chief Scientific Officer | 450,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2025 | Gary Lee Chief Scientific Officer | 56,250 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2025 | Charles Newton Chief Financial Officer | 172,725 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2025 | Charles Newton Chief Financial Officer | 450,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2025 | Charles Newton Chief Financial Officer | 56,250 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2025 | Stephen Hill Chief Operating Officer | 172,899 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2025 | Stephen Hill Chief Operating Officer | 450,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 27, 2025 | Stephen Hill Chief Operating Officer | 56,250 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |